Poster-Disease-modifying Therapy
October 25, 2021
Acapella: B-Cell Repletion in Ocrelizumab-Treated Patients
Background: Ocrelizumab (OCR) is a humanized anti-CD20 monoclonal antibody approved for treatment of relapsing remitting (RRMS) and primary...
Poster-Disease-modifying Therapy
October 25, 2021
Is There Wearing Off with Ocrelizumab? Preliminary Results of Symptom Burden on Ocrelizumab, a Longitudinal Study (SymBOLS).
Background: Ocrelizumab (OCR), a humanized, anti-CD20 antibody therapy approved for multiple sclerosis (MS), is given at 6-month intervals....
Poster-Disease-modifying Therapy
October 25, 2021
Acapella: Real-World Experience with Ocrelizumab: An Observational Study Evaluating Safety in Patients with Relapsing and Progressive MS, Year Four Data
Background: Ocrelizumab (OCR) is a humanized, monoclonal antibody targeting CD20+ B cells and is approved for treatment of relapsing...
Poster-Disease-modifying Therapy
October 25, 2021
Acapella: Hypogammaglobulinemia and JCV Status in Ocrelizumab-Treated Patients, Year Four Data
Background: Ocrelizumab (OCR) is a humanized anti-CD20 monoclonal antibody approved for the treatment of relapsing remitting (RRMS) and...